AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01782339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Chemotherapy
Description: 4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle.
Study NCT02431013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg on Day 1 \& Day 8.
Study NCT02431013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 20 mg on Day 1 \& Day 8.
Study NCT02431013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
Study NCT02431013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
Study NCT03615963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography and coronary angiography
Description: transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
Study NCT03159403 — intervention group
Intervention type: DRUG
Intervention: Oritavancin
Description: This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Study NCT03256578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Life Box Respiratory Function Monitor
Description: The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
Study NCT00745888 — intervention group
Intervention type: OTHER
Intervention: Chemiluminescence Analyzer
Description: measure reactive oxygen species
Study NCT03571035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mandibular movements recordings by a mono vision system
Description: To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
Study NCT03906864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Pathway
Description: The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers.
Study NCT01861392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sensorio-motor training
Study NCT02787304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
Study NCT02787304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00653874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiliChek (jaundice assessment)
Description: assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
Study NCT00653874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiliChek (jaundice assessment)
Description: assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
Study NCT00653874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB)
Description: transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
Study NCT00653874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical asessment of bilirubin (CaB)
Description: Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
Study NCT03042845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tiger cardiac catheter
Description: Tiger cardiac catheter
Study NCT03042845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Judkins 3.5L/4R cardiac catheters
Description: Judkins 3.5L/4R cardiac catheters
Study NCT03225365 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and biopsy sampling
Description: Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression.
Study NCT01118078 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation analysis
Description: Undergo DNA methylation analysis
Study NCT01118078 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Description: Undergo gene expression analysis
Study NCT01118078 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Description: Undergo microarray analysis
Study NCT01118078 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: Undergo RT-PCR
Study NCT01118078 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT02442609 — intervention group
Intervention type: OTHER
Intervention: questionaire
Description: questionaire before surgery
Study NCT02084524 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Malnutrition screening and perioperative nutritional support
Description: * Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines
Study NCT05297357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet weaning scheme
Description: Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
Study NCT02977351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Study NCT02977351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Study NCT01932489 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy of a metastatic lesion.
Study NCT01389739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention to improve continuity of care
Description: Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
Study NCT00830219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole HCl 0.25 mg Tablets
Description: 1 x 0.25 mg, single dose fed
Study NCT00830219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Requip® 0.25 mg Tablets
Description: 1 x 0.25 mg, single dose fed
Study NCT03913234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib, Trastuzumab, Letrozole
Description: Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
Study NCT02815371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle Acupuncture
Description: See above
Study NCT02815371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: See above
Study NCT02815371 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture
Description: See above
Study NCT01928771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Study NCT01928771 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 44 inclusive.
Study NCT00730184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: potassium bicarbonate
Description: 90 mmol/d given as 4 tablets after each meal, with a full glass of water
Study NCT00730184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Given as 4 tablets after each meal, with a full glass of water
Study NCT00427934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
Study NCT00427934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc Placebo
Description: Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
Study NCT03053739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 20mg and Bosentan 62.5mg
Description: Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
Study NCT03053739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 20mg and Placebo
Description: Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
Study NCT00634517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armstrong Albuterol Sulfate Inhalation Aerosol
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
Study NCT00634517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate Inhalation Aerosol
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
Study NCT04635839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose of Unfractionated Heparin
Description: 5,000 units subcutaneous unfractionated heparin every 12 hours
Study NCT04635839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gestational Age-Based Dose of Unfractionated Heparin
Description: * First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours
Study NCT01419457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 800 mg Single Dose
Study NCT03618823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT03618823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT03618823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT03618823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT03618823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT03389165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable hip assist robot
Description: All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
Study NCT04211584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transradial interventions
Description: percutaneous coronary interventions in stable patients - diagnostic and treatment
Study NCT02532400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy
Description: Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
Study NCT02532400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
Study NCT02452047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem+Cilastatin/Relebactam
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
Study NCT03956823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan
Description: Telmisartan group: telmisartan 80 mg once a day
Study NCT03956823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine group: amlodipine 5 mg once a day
Study NCT01812551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
Study NCT01812551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
Study NCT02625727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
Study NCT02625727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid combined corticosteroid
Description: compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
Study NCT01242358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Capnographic monitoring
Study NCT01242358 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring
Study NCT01246739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Description: Adrenalectomy (open or laparoscopic)
Study NCT04151797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician
Study NCT01684332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam
Study NCT02452047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistimethate sodium (CMS)
Description: Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
Study NCT02452047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem+Cilastatin
Description: Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
Study NCT02452047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to CMS
Description: Placebo to CMS IV infusion once every 12 hours
Study NCT00927407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to the scalp for 30 minutes
Study NCT00927407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malathion lotion 0.5%
Description: Malathion lotion 0.5% applied to scalp for 12 hours
Study NCT00499122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00499122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00499122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00499122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV 002
Study NCT01657617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost Stereotactic Body Radiation Therapy
Description: The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy.
Study NCT03057574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa
Description: Patients must be prescribed Follitropin Alfa (Gonapure®)